The ATP Sensitive Potassium Channel (KATP) Is a Novel Target for Migraine Drug Development
June 2023
in “
Frontiers in Molecular Neuroscience
”
Studysummary This review suggests that blocking the ATP-sensitive potassium (K ATP) channel, particularly the Kir6.1/SUR2B subtype, may prove effective in treating migraines, with preclinical data supporting this approach; however, human studies are absent, and potential side effects could complicate clinical use.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on frontiersin.org →